HUP0102473A2 - Benzocikloheptapiridin-származékok és daganatellenes hatóanyagok kombinációja daganatos betegségek kezelésére - Google Patents

Benzocikloheptapiridin-származékok és daganatellenes hatóanyagok kombinációja daganatos betegségek kezelésére

Info

Publication number
HUP0102473A2
HUP0102473A2 HU0102473A HUP0102473A HUP0102473A2 HU P0102473 A2 HUP0102473 A2 HU P0102473A2 HU 0102473 A HU0102473 A HU 0102473A HU P0102473 A HUP0102473 A HU P0102473A HU P0102473 A2 HUP0102473 A2 HU P0102473A2
Authority
HU
Hungary
Prior art keywords
cancer
combination
proliferative diseases
administered
effective amount
Prior art date
Application number
HU0102473A
Other languages
English (en)
Inventor
Walter R. Bishop
Joseph J. Catino
David L. Cutler
Ronald J. Doll
Ashit Ganguly
Viyyoor Girijavallabhan
Paul Kirschmeier
Ming Liu
Loretta L. Nielsen
Original Assignee
Schering Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27385940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0102473(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp. filed Critical Schering Corp.
Publication of HUP0102473A2 publication Critical patent/HUP0102473A2/hu
Publication of HUP0102473A3 publication Critical patent/HUP0102473A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány tárgya új eljárás proliferatív betegségek, elsősorbantüdőrák, hasnyálmirigyrák, vastagbélrák, mieloid leukémia,follikuláris pajzsmirigyrák, hólyagrák, glioma, mielodiszpláziásszindróma, emlőrák vagy prosztatarák kezelésére egy farnezil-protein-transzferáz (FPT) inhibitor, bizonyos megszorításokkal egydaganatellenes hatóanyag és/vagy sugárterápia kombinációjánakalkalmazásával. A találmány szerint úgy járnak el, hogy egy FPTinhibitor, előnyösen egy kondenzált gyűrűs triciklusosbenzocikloheptapiridin-származék hatásos mennyiségével párhuzamosan,egyidejűleg vagy egymást követően, egy daganatellenes hatóanyag,előnyösen 5-fluor-uracil, temozolomid, ciklofoszfamid, vinkrisztin,gemcitabin, paclitaxel vagy egy paclitaxelszármazék hatásosmennyiségét adják be ilyen kezelést igénylő páciensnek, és/vagysugárterápiát alkalmaznak. Ó
HU0102473A 1997-12-22 1998-12-21 Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases HUP0102473A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US99602797A 1997-12-22 1997-12-22
US14352998A 1998-08-28 1998-08-28
US18196998A 1998-10-29 1998-10-29
PCT/US1998/026224 WO1999032114A1 (en) 1997-12-22 1998-12-21 Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases

Publications (2)

Publication Number Publication Date
HUP0102473A2 true HUP0102473A2 (hu) 2002-01-28
HUP0102473A3 HUP0102473A3 (en) 2003-07-28

Family

ID=27385940

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0102473A HUP0102473A3 (en) 1997-12-22 1998-12-21 Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases

Country Status (25)

Country Link
EP (1) EP1041985B1 (hu)
JP (1) JP4502503B2 (hu)
KR (1) KR100700907B1 (hu)
CN (1) CN1129431C (hu)
AR (1) AR017440A1 (hu)
AT (1) ATE317697T1 (hu)
AU (1) AU756762B2 (hu)
BR (1) BR9814419A (hu)
CA (1) CA2315693C (hu)
CL (1) CL2007001889A1 (hu)
CO (1) CO5080764A1 (hu)
CZ (1) CZ298511B6 (hu)
DE (1) DE69833509T2 (hu)
DK (1) DK1041985T3 (hu)
ES (1) ES2255196T3 (hu)
HU (1) HUP0102473A3 (hu)
IL (1) IL136462A0 (hu)
MY (1) MY137303A (hu)
NO (1) NO326832B1 (hu)
NZ (1) NZ504928A (hu)
PE (1) PE20000042A1 (hu)
PT (1) PT1041985E (hu)
SK (1) SK285584B6 (hu)
TW (1) TW581763B (hu)
WO (1) WO1999032114A1 (hu)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2787327B1 (fr) * 1998-12-21 2003-01-17 Aventis Pharma Sa Compositions contenant des inhibiteurs de farnesyle transferase
PT1233787E (pt) * 1999-11-09 2005-04-29 Conseils Rech S Et D Applic Sc Produto contendo um inibidor da transducao dos sinais das proteinas g heterotrimericas em associacao com um outro agente anticanceroso para utilizacao terapeutica no tratamento do cancro
AU2292801A (en) * 1999-12-22 2001-07-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and methods for treatment of breast cancer
CA2397657A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica Inc. Farnesyl protein transferase inhibitor combinations with platinum compounds
AU2001239275A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
EP1263437A2 (en) * 2000-02-29 2002-12-11 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with vinca alkaloids
US20030186925A1 (en) * 2000-02-29 2003-10-02 Palmer Peter Albert Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
JP2003525244A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗腫瘍性アルキル化剤とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
AU2001244167A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
AU2002236813A1 (en) * 2001-01-22 2002-07-30 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
WO2002064142A1 (en) * 2001-02-15 2002-08-22 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with antiestrogen agents
AU2002352941A1 (en) * 2001-11-30 2003-06-17 Schering Corporation Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer
WO2003047586A1 (en) * 2001-12-03 2003-06-12 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
WO2008022535A1 (fr) * 2006-08-09 2008-02-28 Tian Jin Tasly Group Co., Ltd. Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique
CN105198758A (zh) * 2015-09-22 2015-12-30 湖南大学 一种高纯度(z)-他莫昔酚的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
JPH06504772A (ja) * 1990-12-18 1994-06-02 ザ　ウエルカム　ファウンデーション　リミテッド 抗癌剤の薬効を増強し抗多剤耐性を有する薬剤
JP2767176B2 (ja) * 1992-12-15 1998-06-18 大塚製薬株式会社 抗癌剤
US5637688A (en) * 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US6083985A (en) * 1995-08-09 2000-07-04 Banyu Pharmaceutical Co., Ltd. Medicinal composition
TW350844B (en) * 1995-12-22 1999-01-21 Schering Corp Tricyclic amides useful to inhibition of G-protein function and for treatment of proliferative diseases
CZ297979B6 (cs) * 1996-03-12 2007-05-16 Pg-Txl Company, L. P. Kompozice obsahující protinádorové lécivo konjugované s ve vode rozpustným polymerem, její pouzití pro výrobu léciva a implantovatelná lékarská pomucka
JP2000507584A (ja) * 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質転移酵素の阻害剤
CA2251716A1 (en) * 1996-04-15 1997-10-23 W. Gillies Mckenna Sensitization of cells to radiation and chemotherapy
JP2000513711A (ja) * 1996-04-18 2000-10-17 メルク エンド カンパニー インコーポレーテッド 癌の治療法
EP0934270A1 (en) * 1996-05-30 1999-08-11 Merck & Co., Inc. A method of treating cancer
WO1998032376A1 (en) * 1997-01-29 1998-07-30 Picker Medical Systems, Ltd. Predictive bolus tracking
NZ337283A (en) * 1997-02-18 2001-02-23 Canji Inc Use of a tumor suppressing nucleic acid which encodes wild type p53 or retinoblastoma proteins and paclitaxel derivative or a polyprenyl-protein transferase inhibitor for the treatment of neoplasms

Also Published As

Publication number Publication date
DK1041985T3 (da) 2006-06-19
PE20000042A1 (es) 2000-02-17
CO5080764A1 (es) 2001-09-25
DE69833509T2 (de) 2006-10-26
AU1907299A (en) 1999-07-12
BR9814419A (pt) 2000-10-10
CA2315693A1 (en) 1999-07-01
JP2001526224A (ja) 2001-12-18
EP1041985B1 (en) 2006-02-15
KR100700907B1 (ko) 2007-03-29
AU756762B2 (en) 2003-01-23
SK8982000A3 (en) 2001-04-09
ES2255196T3 (es) 2006-06-16
NZ504928A (en) 2004-12-24
CL2007001889A1 (es) 2008-01-11
MY137303A (en) 2009-01-30
CZ298511B6 (cs) 2007-10-24
WO1999032114A1 (en) 1999-07-01
TW581763B (en) 2004-04-01
ATE317697T1 (de) 2006-03-15
JP4502503B2 (ja) 2010-07-14
SK285584B6 (sk) 2007-04-05
NO20003229L (no) 2000-08-22
DE69833509D1 (de) 2006-04-20
CA2315693C (en) 2010-11-30
NO326832B1 (no) 2009-02-23
CZ20002236A3 (cs) 2001-04-11
CN1284875A (zh) 2001-02-21
PT1041985E (pt) 2006-07-31
CN1129431C (zh) 2003-12-03
KR20010033452A (ko) 2001-04-25
NO20003229D0 (no) 2000-06-21
HUP0102473A3 (en) 2003-07-28
EP1041985A1 (en) 2000-10-11
AR017440A1 (es) 2001-09-05
IL136462A0 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
HUP0102473A2 (hu) Benzocikloheptapiridin-származékok és daganatellenes hatóanyagok kombinációja daganatos betegségek kezelésére
Jaffe et al. Osteosarcoma: evolution of treatment paradigms
HRP20131235T1 (hr) Produljeno vrijeme za napredovanje bolesti ili za preživljavanje uporabom pertuzumaba kod pacijenata koji boluju od raka jajnika
CY1120445T1 (el) Συνδυασμοι και τροποι χορηγησης θεραπευτικων παραγοντων και θεραπεια συνδυασμου
MX2023014405A (es) Terapia combinada que comprende un inhibidor de mat2a y un inhibidor de prmt de tipo ii.
MX2021002886A (es) Terapia de combinacion para el tratamiento de cancer de mama triple negativo.
TW200744636A (en) Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents
ECSP003637A (es) Inhibidores triciclicos de poli (adp-ribosa) polimerasas
HRP20110960T1 (hr) Kombinacije terapijskih sredstava za liječenje raka
BRPI0510657A (pt) tratamento com cisplatina e com um inibidor de egfr
HK1046093A1 (en) Docetaxel in combination with rhumab her2 for the treatment of cancers.
CZ309247B6 (cs) 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru
RS20050522A (en) Protein kinase inhibiting tricyclic compounds that increase the effects of anti-neoplastic agents and therapeutic radiation
NO20066056L (no) Behandling med Gemcitabin og en EGFR-inhibitor
MXPA03010121A (es) Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales.
TW200603804A (en) Treatment with irinotecan (cpt-11) and an EGFR-inhibitor
BG108072A (en) The use of epothilone derivatives for the treatment of refractory tumors
BRPI0517075A (pt) uso de um inibidor de cinase de receptor de fator de crescimento epidérmico e radiação de ionização para tratamento de cáncer
TW200608959A (en) Treatment with oxaliplatin and an egfr-inhibitor
MX2024006168A (es) Composicion farmaceutica y uso de la misma.
NO20044498L (no) Kombinasjonsterapi for behandling av cancer
MX2007013830A (es) Terapia de combinacion.
KR960700734A (ko) 사람 암에 대한 시스플래틴/타목시펜 배합 치료(Combination cisplatin/tamoxifen therapy for human cancers)
Oster Chemotherapy before radiotherapy and/or surgery for locally advanced squamous cell carcinomas of the head and neck
MX9305737A (es) Metodos para evitar la resistencia a drogas multiples en celulas decancer.

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished